Semaglutide Dosage Guide: Escalation Schedule, Timing, and Side Effect Management

What Is Semaglutide and How Does It Work?

Semaglutide is a synthetic analog of human GLP-1, a hormone secreted by intestinal L-cells in response to food intake. Natural GLP-1 has a half-life of roughly 2 minutes because the enzyme DPP-4 rapidly degrades it. Semaglutide achieves a half-life of approximately one week through two structural modifications: substitution of alanine at position 8 with alpha-aminoisobutyric acid (conferring DPP-4 resistance) and attachment of a C18 fatty diacid chain via a linker at position 26 (enabling albumin binding and extended plasma half-life).

This long half-life is what makes once-weekly dosing pharmacologically viable and why steady-state concentration is not reached until 4-5 weeks of regular injections, regardless of the dose. The early weeks of a semaglutide course are not at therapeutic steady-state even if the dose is adequate on paper.

At the receptor level, semaglutide activates GLP-1 receptors across several tissues simultaneously:

• Pancreatic beta cells: glucose-dependent insulin secretion increases; glucagon from alpha cells decreases
• Hypothalamus and brainstem: appetite-regulating centers receive satiety signals that reduce food intake and shift food preferences away from high-calorie options
• Gastric smooth muscle: gastric emptying slows, extending the feeling of fullness after meals
• Liver: hepatic glucose production decreases through glucagon suppression

The appetite and gastric emptying effects are central to weight loss. In the STEP trial program, Wegovy at 2.4 mg produced an average body weight reduction of approximately 15% over 68 weeks, compared to about 2.4% with placebo, with both groups on lifestyle intervention.

The Official Escalation Schedule

The slow escalation protocol exists for one reason: the GI tract needs time to adapt. Nausea, vomiting, and diarrhea are dose-dependent and most intense when the dose is raised quickly. Both Ozempic and Wegovy use a phased ramp-up, though the target doses differ by indication.

Wegovy (Semaglutide for Weight Management)

If GI side effects are significant at any escalation step, the prescribing physician may delay the next dose increase by an additional 4 weeks. Spending 8 weeks at a given dose before escalating is a recognized strategy for improving tolerability, particularly in patients with a history of GI sensitivity. The maintenance effect does not require reaching 2.4 mg in all patients: some respond well at 1 mg or 1.7 mg and may continue at a lower maintenance dose if the physician and patient agree.

Ozempic (Semaglutide for Type 2 Diabetes)

Ozempic doses of 1 mg and 2 mg are used off-label for weight management in clinical practice when Wegovy is unavailable or when a physician is managing both diabetes and obesity in the same patient. The pharmacology is identical; only the approved indication differs.

Injection Technique and Timing

Where to inject

Semaglutide is injected subcutaneously into the abdomen (at least 2 inches from the navel), the front of the thigh, or the upper arm. Rotate injection sites each week to reduce local lipodystrophy and injection site reactions. Avoid injecting into scar tissue, bruised skin, or areas with significant subcutaneous lipomas.

Which day of the week

Any consistent day works. Most people anchor it to a day with a reliable anchor (the same day each week, a specific morning routine). If a dose is missed: inject as soon as remembered if there are at least 5 days until the next scheduled dose. If less than 5 days remain, skip the missed dose and resume on the next scheduled day. Never double-dose.

Time of day

Semaglutide's once-weekly half-life means time of day does not materially affect the pharmacokinetic profile the way it does with peptides that have short half-lives. However, many patients find morning injection preferable because peak nausea (typically 1-4 hours post-injection) then falls during waking hours when it is easier to manage rather than disrupting sleep. Evening injection is also reported as workable when morning routines are disrupted. This is user preference, not clinical requirement.

With or without food

Semaglutide can be injected regardless of food intake. Unlike short-acting GLP-1 agonists such as exenatide, which are specifically dosed before meals, semaglutide's continuous receptor engagement means meal timing relative to injection is not pharmacologically meaningful for a weekly formulation.

Managing Side Effects Through Dosing Strategy

The most common side effects of semaglutide are GI-related: nausea (very common, especially in weeks 1-12 and at each escalation), vomiting, diarrhea, and constipation. These typically decrease after 4-8 weeks at a stable dose as the GI tract adapts. Strategies supported by clinical experience and patient reports:

Semaglutide vs Tirzepatide: Dosing Comparison

The dose numbers are not directly comparable between the two drugs because they have different molecular weights, receptor selectivities, and affinities. Comparing 2.4 mg semaglutide to 15 mg tirzepatide numerically is not meaningful. What matters clinically is the effect profile: tirzepatide has shown greater average weight loss in trials, largely attributed to the added GIP receptor activity. See the full semaglutide vs tirzepatide comparison for a detailed breakdown.

Compounded Semaglutide: 2026 Context

Between 2022 and 2025, FDA-declared shortages of Ozempic and Wegovy allowed compounding pharmacies and 503B outsourcing facilities to produce semaglutide for dispensing. The FDA lifted the shortage designation for Wegovy in early 2025, and subsequent enforcement action against compounders has narrowed access to compounded semaglutide significantly by mid-2026.

Where compounded semaglutide is still legally accessible through 503A or 503B compounders, the base molecule is the same semaglutide free acid or sodium salt. However, compounded formulations are not FDA-approved, have not undergone the same sterility and stability testing, and may vary in concentration and excipient composition. Dosing instructions for compounded semaglutide often use mcg rather than mg (e.g., 250 mcg = 0.25 mg) and require careful calculation when the vial concentration differs from branded pen concentration.

The branded Ozempic pen delivers preset doses at a fixed concentration (0.34 mg/mL or 1.34 mg/mL depending on pen). Compounded vials require drawing a specific volume based on concentration, which introduces calculation risk. If using a compounded form, confirm the vial concentration with the dispensing pharmacy and verify the draw volume before injection.

When to Expect Results

Semaglutide's long half-life means meaningful steady-state plasma concentration is not reached until 4-5 weeks of consistent weekly dosing. Patients on the initiation dose (0.25 mg) for the first four weeks are primarily building tolerance, not achieving therapeutic effect. The timeline for common benchmarks:

• Weeks 1-4: GI adaptation; minimal weight effect at 0.25 mg; some patients notice reduced hunger
• Weeks 5-12: First measurable weight loss at 0.5 mg and 1 mg doses; early body weight changes of 2-5% reported in trials
• Weeks 13-20: Approaching or at 2.4 mg maintenance; appetite suppression well-established; cumulative weight loss 8-12% in responsive patients
• Months 6-12: Peak weight loss curve in STEP trials; 12-15% average in the semaglutide arm with lifestyle support
• Beyond 12 months: Weight is largely maintained with continued treatment; discontinuation is associated with weight regain in most patients

Important Safety Considerations

Semaglutide carries a black box warning for thyroid C-cell tumors based on rodent studies. The relevance to humans is not established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use semaglutide. Additional contraindications and cautions include pancreatitis history (discuss risk/benefit with physician), severe gastroparesis, and severe GI disease.

Hypoglycemia risk is very low with semaglutide as monotherapy because its insulin-stimulating effect is glucose-dependent (it does not trigger insulin release at normal or low glucose levels). Risk increases when semaglutide is combined with sulfonylureas or insulin, in which case those medications may need dose reduction.